Roivant Sciences Ltd. (NASDAQ:ROIV) Position Boosted by TOMS Capital Investment Management LP

TOMS Capital Investment Management LP lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 46.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,885,000 shares of the company’s stock after buying an additional 1,870,000 shares during the quarter. Roivant Sciences makes up about 2.5% of TOMS Capital Investment Management LP’s investment portfolio, making the stock its 9th largest position. TOMS Capital Investment Management LP owned about 0.81% of Roivant Sciences worth $69,620,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Roivant Sciences in the fourth quarter worth $39,000. GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after buying an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after buying an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company’s stock worth $89,000 after buying an additional 3,426 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 1.6 %

Roivant Sciences stock opened at $11.19 on Tuesday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The company has a market cap of $7.98 billion, a price-to-earnings ratio of -74.60 and a beta of 1.25. The firm’s fifty day moving average is $10.35 and its 200 day moving average is $11.14.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th.

Insider Activity

In other news, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 218,041 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,395,541 shares of company stock valued at $14,922,538. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.